RetinalGenix Technologies Inc (OTC Pink: RTGN) is a pre-revenue medical technology company developing retinal imaging, pharmacogenetic testing, and genetic diagnostic products targeting eye disease and systemic conditions. The company has generated no significant product revenue as of its 10-K filed April 15, 2026, covering fiscal years ended December 31, 2025 and 2024. Its wholly owned subsidiary, DNA/GPS Inc., links high-resolution retinal imaging to retinal and systemic disease biomarkers through pharmacogenetic mapping. The company is conducting an Institutional Review Board study with Pearl IRB to evaluate the genetic basis for outcomes in wet macular degeneration patients receiving intraocular injections, with phlebotomy services provided by Seven Springs Surgery Center. RetinalGenix intends to begin selling swab-based genetic tests directly to patients in 2026, with manufacturing, distribution, and clinical processing handled by a third-party genetic testing company. The company has financed operations through equity offerings, raising approximately $3.0 million from private placement of 3,070,000 shares between 2019 and January 2022. Jerry Katzman serves as President and Chief Executive Officer.

Revenue model

No product revenue has been generated as of the fiscal years ended December 31, 2025 and 2024. The company has funded operations through private placements and equity offerings. The intended revenue model upon commercialization includes direct-to-patient sales of swab-based genetic tests, with third-party partners handling manufacturing and clinical processing.

Products and services

Swab-based pharmacogenetic tests for patient genetic profiling (planned commercial launch 2026); high-resolution retinal imaging linked to disease biomarkers through DNA/GPS Inc.; IRB study personalizing medical evaluations for wet macular degeneration patients receiving intraocular injections; an Eye Care Anonymized AI database for genetic research.

Customers and end markets

Target end markets include patients with wet macular degeneration and other sight-threatening diseases, as well as physicians and care providers who may use genetic and retinal imaging data for diagnosis and treatment decisions. No paying customers are disclosed in the filing.

Value-chain role

RetinalGenix occupies a development-stage role, conducting clinical studies and IRB research while outsourcing manufacturing, distribution, clinical processing, genetic reporting, and analytics to third-party partners. Jerry Katzman (President and CEO) is identified as a key-person dependency.

Geographic exposure

The company operates from an office suite under a lease entered September 2024 with a monthly payment of $650 (escalating to $690 over three years). No geographic revenue breakdown is disclosed. An expansion of the IRB study to multistate physicians is planned for winter 2026.

Source: SEC 10-K, filed 2026-04-15

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Accelerate Diagnostics, Inc Accuray Inc Apyx Medical Inc CVRx Inc Owlet Inc KORU Medical Systems Inc Tactile Systems Technology Inc Stereotaxis Inc